Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia -

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Cancers | Haematological disorders
Summary
RCT (n=405) found that blinatumomab resulted in significantly longer overall survival than chemotherapy (7 vs. 4 months; HR for death = 0.71; 95% CI, 0.55-0.93; p=0.01) among adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.
UKMi comment
Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19. It is licensed in UK for the treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia.
Related links: